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Background: Radix ophiopogonis polysaccharide (ROP) has been found to be effective against 
myocardial ischemia. One of main problems with its use is its short in-vivo half-life, which makes 
the development of an effective delivery system necessary. To achieve better therapeutic effects 
and patient compliance by prolonging its retention in plasma and increasing its distribution in 
targets, ROP was PEGylated (PEG, polyethylene glycol) in this study.
Methods: Through a moderate coupling reaction between hydroxyl-activated ROP and amino-
terminated methoxy-PEG (mPEG) (30 or 40 kDa), together with a greater than 1 molar ratio of 
ROP to mPEG in reaction, long-circulating and potentially bioactive PEGylated ROPs, with PEG 
grafting number of ∼1.0, were prepared, characterized, and the pharmacokinetics evaluated.
Results: Relative to ROP, whose half-life was approximately 0.7 hours, the two conjugates 
prepared, following intravenous administration, showed markedly prolonged retention in 
systemic circulation with half-lives in blood of 78.4 and 88.3 hours, respectively. When given 
subcutaneously, their in-vivo mean residence times were further markedly prolonged by the 
slow absorption phase. They were found to be well absorbed after subcutaneous administration, 
with absolute bioavailability being 75.4% and 43.9%, respectively.
Conclusion: With apparent molecular masses not exceeding 43 kDa, the conjugates prepared 
have been and will be demonstrated to have prominent advantages for ROP delivery, such as: 
the good absorption following subcutaneous, intramuscular, or other ways of administration; 
the effective utilization of the enhanced permeability and retention effect caused by ischemia; 
and the rapid diffusion within target tissues.
Keywords: radix ophiopogonis polysaccharide, polyethylene glycol, conjugation, pharma-
cokinetics
Introduction
Presently, there are many macromolecular drugs, either marketed or developing,   having 
a short plasma half-life following injection administration due to immunogenicity, low 
stability in vivo, and/or rapid glomerular filtration. Several approaches, including loading 
the drug in various long-circulating colloidal delivery systems and modifying the drug 
chemically, have been developed to improve the pharmacokinetic and   pharmacodynamic 
profiles of such drugs.1,2 Among these approaches, polymer conjugation, the process of 
covalent attachment of polymer chain(s) to a drug   molecule, has grown fast in the last 
few years and has already resulted in a number of products available in the marketplace.2,3 
Many synthetic, semisynthetic, and natural polymers have been investigated as candi-
dates for polymer conjugation, among which, polyethylene glycol (PEG) is the most 
successful one due to its unique advantages: (1) little antigenicity, immunogenicity and 
toxicity; (2) high solubility in many   solvents; (3) highly hydrated and flexible backbone; 
and (4) approval by the Food and Drug Administration for human use in injectable 
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  formulations. PEGylation has been becoming the strategy of 
choice for optimizing delivery of parenteral agents.4,5
Radix ophiopogonis polysaccharide (ROP), a natural 
graminan-type fructan with weight average molecular weight 
(Mw) of ∼5 kDa, has been found to be very effective against 
myocardial ischemia.6,7 However, due to its unusual   properties, 
ROP is rarely absorbed orally, and is rapidly excreted by 
the kidneys following intravenous administration.8,9 This 
limits its efficacy and clinical application remarkably. In a 
previous study,10 it was found that the effects of PEGylation 
on the bioactivity and pharmacokinetics of ROP mainly 
depend on the grafting degree and the molecular weight of 
the conjugate, respectively. More specifically, only when the 
apparent molecular weight of the conjugate approached the 
glomerular filtration threshold for PEG (∼30 kDa) would its 
plasma elimination reduce abruptly. In general, the conjuga-
tion causes the reduction in the bioactivity of ROP; however, 
well preserved bioactivity is observed when the grafting 
degree of the conjugate is lower. In another study, it was 
found that due to the enhanced permeability and retention 
(EPR) effect caused by ischemia,11,12 the distribution of ROP 
(∼2 nm) is approximately twofold higher in myocardial 
ischemic rat hearts than in normal ones.13 However, the 
utilization of the EPR effect is significantly limited by the 
rapid glomerular filtration of ROP, making the increase far 
from ideal. To achieve better therapeutic effects and patient 
compliance by prolonging its retention in plasma and increas-
ing its distribution in targets, ROP was PEGylated in this 
study through the reaction of hydroxyl-activated ROP with 
amino-terminated methoxy-PEG (mPEG) (30 or 40 kDa) 
under a greater than 1 molar ratio of ROP to mPEG. By 
PEGylating ROP in this way, two conjugates, with mPEG 
grafting degree of ∼1.0 and thus potentially well preserved 
bioactivity, were prepared, purified, and characterized, and 
the pharmacokinetics evaluated.
Materials and methods
Materials and animals
ROP was prepared as described previously.14 Briefly, water-
soluble components of the tuberous roots of Ophiopogon 
japonicus (Cixi, Zhejiang province, China) were extracted 
with ten volumes of water at 95°C–100°C, followed by 
centrifugation. After being concentrated to a suitable level 
(1 mL of extract was pharmacodynamically equivalent to 1 g 
of the roots), the extract was precipitated by the addition of 
five volumes of 95% ethanol. The resulting precipitate was 
redissolved in water and purified by ultrafiltration (Mw cut-
off value of membrane: 10,000) under pressure (0.3 MPa). 
Products with molecular weights estimated to be less than 
10,000 were further purified using DEAE Sepharose® Fast 
Flow and Sephadex® G-25 columns (Pharmacia, Uppsala, 
Sweden) in tandem, eluted with water to obtain ROP. Linear 
amino-terminated PEG methyl ethers (mPEG-NH2) with Mw 
30 and 40 kDa were purchased from Jenkem Technology 
Co Ltd (Beijing, China). p-Nitrophenyl chloroformate and 
4-N, N-(dimethylamino) pyridine (DMAP) were purchased 
from Fluka (Buchs, Germany). Fluorescein isothiocyanate 
(FITC) was purchased from Sigma (St Louis, MO). Extra 
dry dimethyl sulfoxide (DMSO) was purchased from Acros 
Organics (Geel, Belgium). Dichloromethane (CH2Cl2) 
and pyridine from Sinopharm Chemical Reagent Co Ltd 
  (Shanghai, China) were dried over CaH2 and KOH, respec-
tively, and distilled prior to use. All other chemicals were of 
reagent grade and purchased from commercial sources.
Male Sprague-Dawley rats (approximately 6–7 weeks 
old) were supplied by Lab Animal Center of the Shanghai 
University of Traditional Chinese Medicine. They were 
kept in an environmentally controlled breeding room for 
4 days before starting the experiments, and fed with standard 
laboratory food and water ad libitum. The Animal Ethical 
Experimentation Committee of the Shanghai University of 
Traditional Chinese Medicine, according to the requirements 
of the National Act on the Use of Experimental Animals 
(People’s Republic of China), approved all procedures of 
the animal experiments.
Preparation and characterization of 
PEGylated ROPs
PEGylated ROPs were synthesized through a coupling reac-
tion between hydroxyl-activated ROP and amino-terminated 
mPEG.10
In detail, the hydroxyl groups of ROP were activated with 
p-nitrophenyl chloroformate in the presence of DMAP as a 
catalyst. ROP (1 g, 0.21 mmol), p-nitrophenyl chloroformate 
(1 g, 4.97 mmol), and DMAP (100 mg) were dissolved in 
40 mL of a mixture of DMSO, CH2Cl2, and pyridine (2:1:1 in 
volume ratio) and kept at 0°C for 2 hours. The product 
was precipitated in 360 mL of a cold diethyl ether/ethanol 
(1:1, v/v) mixture and filtered. The final product was washed 
at least nine times with the precipitation reagent and dried 
in vacuo for 24 hours. The yield was approximately 90%. 
The p-nitrophenyl carbonate content of each activated ROP, 
which was determined spectrometrically,15 was approxi-
mately 13 per 100 fructose units.
The activated ROP and mPEG-NH2 (30 or 40 kDa) 
were dissolved in a mixture of DMSO/pyridine (1:1, v/v). 
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The molar ratio of ROP to mPEG-NH2 was set at 10:1 in 
this study so that conjugates with a PEG grafting number 
approaching 1.0 were prepared. The reaction mixture was 
stirred for 4 days at room temperature and then added to a 
cold diethyl ether/ethanol (3:1, v/v) mixture with stirring. The 
white precipitate was collected, washed with an excess of the 
precipitation reagent, and dried in vacuo. The product was 
dissolved in a 0.01 M NaOH aqueous solution to hydrolyze 
the residual p-nitrophenyl groups on the conjugate, followed 
by dialysis and lyophilization.
Characterization of conjugates was carried out by high-
performance gel permeation chromatography (HPGPC) in 
conjunction with anthrone-sulfuric acid colorimetry.10 The 
high-performance liquid chromatography (HPLC) system 
consisted of a Waters liquid chromatograph and a Waters 
2414 refractive index detector (Waters Corporation, Milford, 
MA). After characterization, the conjugates were labeled with 
FITC according to a method previously used.10
Assay of FITC-labeled conjugates
The assay system consisted of an Agilent 1200 series 
  (Agilent Technologies, Santa Clara, CA) HPLC with a fluo-
rescence detector set at λex 495 nm and λem 515 nm. Samples 
were separated by HPGPC using an 8 mm × 300 mm 
  Shodex® OHpak SB-803 HQ gel-filtration column (Tokyo, 
Japan). The eluent was 0.1 M phosphate buffer (pH 7.4) 
delivered at a flow rate of 0.5 mL/min. The chromatographic 
procedures were performed at 30°C.
Pharmacokinetic study
FITC-labeled PEGylated ROP was administered intrave-
nously to rats via tail vein at a dose of 50 mg/kg. Blood 
samples (approximately 400 µL) were obtained from the 
orbital sinus at the specified time points and then centrifuged 
at 3000 rpm for 10 minutes. The separated plasma was frozen 
at −20°C until assay.
To a 100 µL portion of each plasma sample, 40 µL of 
1 M perchloric acid was added. The mixture was vortexed 
and then centrifuged at 10,000 rpm for 1 minute to precipi-
tate denatured proteins. The supernatant was neutralized by 
the addition of 30 µL of 1 M NaOH. After centrifugation at 
10,000 rpm for 1 minute again, 10 µL of the supernatant was 
assayed by the method described above.
Data analysis
Data were expressed as means ± standard deviations. 
  Statistical analyses were assessed using Student’s t-test. 
  Statistically significant differences were indicated by P-values 
of ,0.05. The Drug and Statistics (DAS) 2.0 pharmacokinetic 
program (Chinese Pharmacology Society, Beijing, China)
was used to calculate pharmacokinetic parameters such as 
area under the curve (AUC), mean residence time (MRT), 
terminal phase half-life (t1/2), total volume of distribution 
(Vss), systemic clearance (CL), maximal concentration (Cmax), 
time to maximal concentration (Tmax), and bioavailability by 
noncompartmental analysis.
Results and discussion
Preparation of PEGylated ROPs
Site-selective PEGylation of drugs is always preferred as 
it allows easier purification, characterization, and control 
of products and, most importantly, better preservation 
of bioactivity of drugs. Several strategies, such as thiol 
PEGylation,16 accessing specific protein amino groups in an 
appropriate solvent,17 blocking some of the reactive groups 
with a reversible protecting group,18 and glycoPEGylation,19 
had been successfully applied for the site-selective 
  PEGylation of peptides and proteins. However, due to the 
lack of structure-activity knowledge and reactivity-specific 
functional group(s), the site-selective PEGylation of poly-
saccharides is much more difficult than that of peptides 
and proteins. The strategy, using few high molecular mass 
PEG chains rather than a higher number of low molecular 
ones, is therefore especially important for the PEGyla-
tion of polysaccharide-based drugs. In addition, with the 
exception of conjugation sites, no changes in the other 
sites of polysaccharides are preferred. Several methods 
had been reported to PEGylate neutral polysaccharides 
like dextran20–23 and inulin.24,25 Among these methods, the 
one used in the study, which utilizes a moderate coupling 
reaction between the hydroxyl-activated polysaccharide 
and the amino-terminated mPEG, was believed to be more 
suitable for PEGylation of polysaccharide-based drugs 
than those that cause charged conjugates21 or require highly 
alkaline conditions for the coupling,23 since it allows the 
unreacted activated hydroxyls of polysaccharide to return 
to their original form easily by hydrolysis in a weakly 
alkaline solution and thus ensures the least influence on the 
polysaccharide structure and, in turn, on bioactivity. This, 
coupled with a greater than 1 molar ratio of ROP to mPEG 
in reaction, makes sure that the conjugates, with mPEG 
grafting degree of ∼1.0 and thus potentially well preserved 
bioactivity, were prepared. It was found that excessive ROP 
was easily removed from products by dialysis due to the 
great disparity in apparent molecular mass between ROP 
and the conjugates.
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Characterization of conjugates and  
FITC-labeled conjugates
Characterization of PEGylated ROPs is pretty challenging 
because both PEG and ROP are neutral and hydrophilic 
macromolecules as well as lack chromophoric groups. To 
date, nuclear magnetic resonance (NMR) and gel permeation 
chromatography (or size-exclusion chromatography) are the 
most commonly used methods to characterize PEGylated 
polysaccharides. Since ROP is a fructan and thus lacks an 
anomeric proton, the  1H NMR method used to determine 
the grafting degree of PEGylated dextrans20 was found to be 
inapplicable for PEGylated ROPs. It was also found that the 
confirmation of PEGylation by 1H NMR or Fourier transform 
infrared spectroscopy was impractical due to the very few 
carbamate bonds in the conjugates prepared. In this study, they 
were therefore characterized by HPGPC in conjunction with 
the carbohydrate-specific anthrone-sulfuric acid colorimetry. 
PEGylation was affirmed mainly by (1) the slightly left-shifted 
HPGPC peaks and increased polydispersity indices of the 
conjugates when compared with the mPEG agents used, 
and more importantly, (2) the positive chromogenic reaction 
between the anthrone-sulfuric acid reagent and the eluate 
corresponding to the HPGPC peak for each conjugate. The 
calculated apparent molecular masses and PEG-grafting num-
bers for the conjugates are listed in Table 1. For convenience, 
in the following description, the conjugates are denoted as 
0.99P30k-R and 0.98P40k-R, respectively. Due to the lack of specific 
microassay methods, the conjugates were pre-labeled with 
FITC to study their pharmacokinetics. In terms of the very low 
substitution degrees (approximately 0.25 and 0.15 mol FITC 
per mol 0.99P30k-R and 0.98P40k-R, respectively), pharmacokinetic 
behaviors of the FITC-labeled conjugates were believed to be 
similar to those of native conjugates.
Validation of the determination method 
for pharmacokinetic study
FITC pre-labeling coupled with HPGPC was used in this 
study to determine the conjugates in rat plasma and urine. 
The method was validated for specificity, linearity, precision, 
accuracy, sensitivity, recovery, and stability. The results 
showed that the method was specific for the conjugates and no 
obvious breakages of the conjugates were observed during the 
study (Figure 1). The typical retention times for FITC-labeled 
ROP, 0.99P30k-R, and 0.98P40k-R were approximately 19.4, 14.5, 
and 13.9 minutes, respectively. The linearity between the 
chromatographic peak height and the concentration was 
evident over the concentration range studied (4–972 µg/mL 
and 6–1458 µg/mL for FITC-labeled 0.99P30k-R and 0.98P40k-R, 
respectively), with correlation coefficients larger than 0.998. 
The detection limits for  0.99P30k-R and  0.98P40k-R were both 
approximately 2 µg/mL. The precision and accuracy of 
the method were examined by adding known amounts of 
FITC-labeled conjugates to blank rat plasma. The inter- and 
intraday precisions of analysis were not more than 10%, and 
assay accuracy ranged from 92% to 106% (Table 2). The 
absolute recoveries of FITC-labeled conjugates were tested 
at three quality control levels by comparing the calculated 
concentrations from pretreated plasma samples with those 
found by direct injection of standard solutions at the same 
concentration, which were found to be between 58.9% and 
77.3% (Table 2). Analysis of biosamples for storage and 
freeze-thaw stability testing consistently afforded values that 
Table 1 Characterization of mPEG-ROP conjugates
Materials and conjugates Mn (Da) Mw (Da) Mp (Da) Polydispersity index Grafting degree Designation
ROP 1738 2055 1991 1.18 – –
30 kDa mPEG-NH2 30836 33099 34522 1.06 – –
40 kDa mPEG-NH2 34873 41380 48015 1.19 – –
mPEG30k-ROP 32373 34864 34646 1.08 0.991 0.99P30k-R
mPEG40k-ROP 35724 42721 49479 1.20 0.983 0.98P40k-R
Abbreviations: Mn, number average molecular weight; Mp, peak average molecular weight; Mw, weight average molecular weight; mPEG, methoxy-polyethylene glycol; ROP, 
radix ophiopogonis polysaccharide.
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Figure  1  Representative  chromatograms  for  determination  of  FITC-labeled 
(A) 0.99P30k-R and (B) 0.98P40k-R in rat plasma by HPGPC.
Notes: 1, blank plasma; 2, blank urine; 3, urine samples collected after administration 
of FITC-labeled conjugates; 4, blank plasma spiked with FITC-labeled conjugates; 
5, plasma samples collected after administration of FITC-labeled conjugates.
Abbreviations: FITC, fluorescein isothiocyanate; HPGPC, high-performance gel 
permeation chromatography; P, methoxy-polyethylene glycol; R, radix ophiopogonis 
polysaccharide.
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were nearly identical to those of freshly prepared biosamples 
(the relative error was within ±15%). All the results demon-
strated that the method was accurate, specific, and stable.
Pharmacokinetics of PEGylated ROPs
In a previous study,26 the pharmacokinetics of a long-
circulating and bioactive PEGylated ROP with an average 
1.03 mEPG (20 kDa) residues per single ROP (denoted 
as  1.03P20k-R) was investigated following intravenous or 
subcutaneous administration at three dose levels (9, 20, 
and 50 mg/kg) in rats. An evident linear correlation was 
observed between administration doses and areas under the 
plasma 1.03P20k-R level versus time profile, regardless of the 
administration route. The tissue distribution of 1.04P20k-R 
in mice with normal and ischemic myocardium was also 
  studied.27 The results show that the AUC of  1.04P20k-R in 
ischemic hearts was approximately 1.6-fold greater than in 
normal hearts, indicating that the conjugate still could effec-
tively use the EPR effect caused by ischemia to passively 
target ischemic myocardia.
In this study, pharmacokinetic properties of two more 
long-circulating PEGylated ROPs, namely  0.99P30k-R and 
0.98P40k-R, were evaluated in rats following intravenous or 
subcutaneous administration at a dose of 50 mg/kg. For 
comparison, blood plasma level-time profiles for ROP, 
1.03P20k-R,  0.99P30k-R, and  0.98P40k-R are together shown in 
Figure 2, and main pharmacokinetic parameters are listed 
in Tables 3 and 4. Relative to ROP, whose half-life was 
approximately 0.7 hours, 1.03P20k-R, 0.99P30k-R, and 0.98P40k-R, 
following intravenous administration, showed markedly 
prolonged retention in systemic circulation, with half-lives 
in blood of 35.6, 78.4, and 88.3 hours, respectively. Just as 
for polysaccharides, PEGs, and PEGylated proteins, all of 
the three PEGylated ROPs displayed multicompartmental 
pharmacokinetics (Figure 2A). When the conjugates were 
given subcutaneously, their MRTs were further remarkably 
prolonged by the slow absorption phase. The absorption half-
lives of 1.03P20k-R, 0.99P30k-R, and 0.98P40k-R were 24.9, 24.1, and 
33.2 hours, respectively, approximately 137–188 times that of 
ROP. All the conjugates were found to be well absorbed after 
Table 2 Recovery, precision, and accuracy for the assay of FITC-labeled mPEG-ROP conjugates in rat plasma by HPGPC (n = 5)
Conjugate Concentration (μg/mL) Recovery (%) Accuracy (%) Precision RSD (%)
Intraday Interday
0.99P30k-R 10 58.9 ± 4.7 102 ± 8.2 8.04 8.96
70 77.3 ± 4.4 103 ± 5.9 5.75 8.61
700 61.7 ± 3.1 94.8 ± 4.8 5.05 7.27
0.98P40k-R 10 69.5 ± 6.9  106 ± 10.6 10.0 9.26
100 70.0 ± 5.7 95.5 ± 7.8 8.14 7.45
1000 62.7 ± 1.3 92.4 ± 2.0 2.14 6.93
Abbreviations: FITC, fluorescein isothiocyanate; HPGPC, high-performance gel permeation chromatography; mPEG, methoxy-polyethylene glycol; P, mPEG; R, ROP; 
ROP, radix ophiopogonis polysaccharide; RSD, relative standard deviation.
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Figure 2 Plasma FITC-labeled ROP (open squares), 1.03P20k-R (open circles), 0.99P30k-R (open up-triangles), or 0.98P40k-R (open down-triangles) level versus time profiles following 
(A) intravenous or (B) subcutaneous administration at 50 mg/kg to rats.
Note: Each data point represents the mean ± standard deviation for triplicate experiments.
Abbreviations: conc, concentration; FITC, fluorescein isothiocyanate; P, methoxy-polyethylene glycol; R, ROP; ROP, radix ophiopogonis polysaccharide.
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subcutaneous administration, with absolute bioavailability 
being 68.9%, 75.4%, and 43.9%, respectively. This indicates 
that it is promising to give them in such a more convenient 
and safer way so as to achieve better therapeutic effects 
and patient compliance. After subcutaneous administration, 
macromolecules may be transported to systemic circulation 
directly via blood capillaries or indirectly via lymphatics, 
both of which contribute to the absorption of materials from 
the subcutaneous tissue. Studies have shown that greater 
than 50% of a subcutaneous dose may be taken up by the 
peripheral lymphatics for macromolecules whose molecular 
mass exceeds approximately 20 kDa.28–30 Molecular weight, 
or size, is also thought to be the primary determinant for 
the absorption route of macromolecules after subcutaneous 
administration.29,31 In terms of their molecular masses, the two 
conjugates prepared in this study were, therefore, believed 
to be mainly absorbed into blood indirectly via lymphatics. 
Moreover, according to HPGPC chromatograms obtained in 
the pharmacokinetic study, it was believed that the   majority, 
if not all, of the conjugates transported into lymphatics 
could survive from the lymphatic system and reach blood 
undegraded. With larger hydrodynamic volumes and   longer 
plasma residence times,  0.99P30k-R and  0.98P40k-R are also 
expected to be able to passively target ischemic myocardia 
more effectively by the EPR effect than 1.04P20k-R.
In another study,10 several other PEGylated ROPs (0.8P2k-R, 
4.0P2k-R, 1.1P5k-R, and 5.4P5k-R, with apparent molecular masses 
of 3.8, 10.4, 8.3, and 31.2 kDa, respectively) had been pre-
pared and evaluated in pharmacokinetics. The results, together 
with those obtained here, clearly indicate a sigmoidal-shaped 
relation between the apparent molecular masses and the half-
lives of PEGylated ROPs (Figure 3). The apparent molecular 
mass corresponding to the mean point of the sigmoid is 
25.4 kDa, which is a little lower than the reported glomerular 
filtration threshold for PEG (∼30 kDa).32,33 ROP is a highly 
branched fructan, having a backbone composed of Fruf 
(2 → 1) and a branch of Fruf (2 → 6) Fruf (2 → per average 
2.8 of main chain residues.14 By atom force microscope, it was 
found that ROP appeared to be spherical at a concentration of 
0.1 mg/mL.7 Therefore, mPEG-ROP conjugates were believed 
to be more spherical and have lower flexibility and deform-
ability in blood than linear mPEG agents alone. This allowed 
for their more difficult glomerular filtration, especially when 
their sizes were around the sieving threshold of the glomerular 
  capillary wall (∼10 nm)34 and was believed to be the reason 
for the just-mentioned disparity. This finding also coincides 
Table 3 Rat pharmacokinetic parameters following intravenous administration of 50 mg/kg mPEG-ROP conjugates (means ± SD, n = 3)
Parametera ROP10
1.03P20k-R26
0.99P30k-R 0.98P40k-R
AUC0–∞ (g ⋅ h/L) 0.170 ± 0.024 3.05 ± 0.45 7.30 ± 0.94 23.7 ± 4.5b
MRT0–∞ (hours) 0.826 ± 0.031 22.4 ± 8.0 54.4 ± 12.7 83.2 ± 2.6c
t1/2 (hours)d 0.724 ± 0.004 35.6 ± 9.0 78.4 ± 12.2 88.3 ± 3.0e
Vss (mL/kg) 314 ± 46 853 ± 217 778 ± 109 276 ± 60
CL (L/h per kg) 0.300 ± 0.044 0.017 ± 0.003 0.007 ± 0.001 0.002 ± 0.000
Notes:  aCalculated by noncompartmental moment analysis assuming first-order elimination;  bP , 0.01, compared with  0.99P30k-R;  cP , 0.05, compared with  0.99P30k-R; 
dcalculated from the elimination rate constant (λZ) using the formula t1/2 = 0.693/λZ; eP . 0.05, compared with 0.99P30k-R.
Abbreviations: AUC, area under the curve; CL, systemic clearance; mPEG, methoxy-polyethylene glycol; MRT, mean residence time; P, mPEG; R, ROP; ROP, radix 
ophiopogonis polysaccharide; SD, standard deviation; t1/2, half-life; Vss, total volume of distribution.
Table 4 Rat pharmacokinetic parameters following subcutaneous administration of 50 mg/kg mPEG-ROP conjugates (means ± SD, n = 3)
Parametera ROP 1.03P20k-R26
0.99P30k-R 0.98P40k-R
AUC0–∞ (g ⋅ h/L) 0.160 ± 0.010 2.10 ± 0.46 5.50 ± 0.74 10.4 ± 0.8b
MRT0–∞ (hours) 1.08 ± 0.04 58.4 ± 8.7 89.2 ± 1.3 131 ± 6b
t1/2 (hours)c 0.577 ± 0.082 35.1 ± 15.7 66.8 ± 9.0 89.2 ± 4.4d
ka (×10−2)e     394     2.78     2.87     2.09
Cmax (mg/L) 118 ± 13 43.7 ± 4.5 86.8 ± 17.1 99.4 ± 9.4f
Tmax (hours) 0.444 ± 0.192 18.7 ± 4.6 24.0 ± 0.0 30.0 ± 0.0
F (%)     94.1     68.9     75.4     43.9
CL/F (L/h per kg) 0.328 ± 0.020 0.025 ± 0.005 0.009 ± 0.001 0.005 ± 0.001
Notes: aCalculated by noncompartmental moment analysis assuming first-order elimination; bP , 0.01, compared with 0.99P30k-R; ccalculated from the elimination rate constant 
(λZ) using the formula t1/2 = 0.693/λZ; dP , 0.05, compared with 0.99P30k-R; eestimated as the reciprocal of MAT (MAT = MRTsc − MRTiv); fP . 0.05, compared with 0.99P30k-R.
Abbreviations:  AUC,  area  under  the  curve;  CL,  systemic  clearance;  Cmax,  maximal  concentration;  F,  absolute  bioavailability;  ka,  absorption  rate  constant;  mPEG, 
methoxy-polyethylene glycol; MRT, mean residence time; MRTiv, MRT intravenous; MRTsc, MRT subcutaneous; P, mPEG; R, ROP; ROP, radix ophiopogonis polysaccharide; 
SD, standard deviation; t1/2, half-life; Tmax, time to maximal concentration.
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with the conclusion obtained by Arendshorst and Navar, who 
demonstrated that glomerular filtration of macromolecules 
was related not only to their size and charge but also to their 
shape and rigidity.35 In addition, the sigmoid also indicated 
that mPEG-NH2 with molecular mass above 40 kDa might 
not be suitable for PEGylation of ROP due to both the limited 
further increase in elimination half-life and the increased pos-
sibility of accumulation of the agents in the body.
Conclusion
Through a moderate coupling reaction between hydroxyl-
activated ROP and amino-terminated mPEG with proper 
molecular weight ($20 kDa) together with a greater than 
1 molar ratio of ROP to mPEG in reaction, long-circulating 
PEGylated ROPs, with PEG-grafting degree of ∼1.0 and 
thus potentially well preserved bioactivity, can be prepared. 
Characterization of PEGylated ROPs can be carried out 
by HPGPC in conjunction with the carbohydrate-specific 
anthrone-sulfuric acid colorimetry. With apparent molecular 
masses not exceeding 43 kDa, the conjugates prepared in 
this study have been and will be demonstrated to have the 
variety of prominent advantages for ROP delivery, such 
as the long residence time in blood, the good absorption 
following subcutaneous, intramuscular, or other ways of 
administration, the effective utilization of the EPR effect 
caused by ischemia, and the rapid diffusion within target 
tissues.
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Figure 3 Relationship between the apparent weight average molecular weights and 
the elimination half-lives of PEGylated ROPs.
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